Does the Progestogen Used in Combined Hormonal Contraception Affect Venous Thrombosis Risk?

被引：16

作者：

Han, Leo ^{[1
]}

Jensen, Jeffrey T. ^{[1
]}

机构：

[1] Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97239 USA

来源：

OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA | 2015年 / 42卷 / 04期

关键词：

Progestin; Progestogen; Venous thromboembolism; Oral contraceptive; Drospirenone; 3RD-GENERATION ORAL-CONTRACEPTIVES; V-LEIDEN MUTATION; MYOCARDIAL-INFARCTION; TRANSDERMAL PATCH; ACTIVE SURVEILLANCE; BINDING GLOBULIN; THROMBOEMBOLISM; WOMEN; DROSPIRENONE; SAFETY;

D O I：

10.1016/j.ogc.2015.07.007

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Combined hormonal contraceptives (CHCs) use a combination of estrogen and progestogen to provide contraception. The most important risk of using CHCs is venous thromboembolism (VTE). It is unclear whether the type of progestogen used in a method augments that risk. Although the evidence supporting an increase in thrombosis risk is not conclusive, neither is the evidence supporting the benefit of newer progestogens in terms of tolerability or continuation. The benefits of CHCs outweigh the risks and the absolute risk of VTE remains small. A balanced discussion of potential risks and benefits of particular CHC formulations is warranted during contraception counseling.

引用

页码：683 / +

页数：17

共 64 条

[1] Contraceptive considerations in obese women [J].

不详 .

CONTRACEPTION, 2009, 80 (06) :583-590

[2]

[Anonymous], 2010, Medical eligibility criteria for contraceptive use, V4th

[3] The pharmacokinetics and efficacy of different estrogens are not equivalent [J].

Ansbacher, R .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2001, 184 (03) :255-263

[4] Venous Thromboembolism A Public Health Concern [J].

Beckman, Michele G. ;

Hooper, W. Craig ;

Critchley, Sara E. ;

Ortel, Thomas L. .

AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2010, 38 (04) :S495-S501

[5] Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis [J].

Bird, Steven T. ;

Hartzema, Abraham G. ;

Brophy, James M. ;

Etminan, Mahyar ;

Delaney, Joseph A. C. .

CANADIAN MEDICAL ASSOCIATION JOURNAL, 2013, 185 (02) :E115-E120

[6] Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism [J].

Bitzer, Johannes .

JOURNAL OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE, 2013, 39 (03) :156-159

[7] Thrombophilias and gynaecology [J].

Bloemenkamp, KWM ;

Helmerhorst, FM ;

Rosendaal, FR ;

Vandenbroucke, JP .

BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2003, 17 (03) :509-528

[8] ENHANCEMENT BY FACTOR-V LEIDEN MUTATION OF RISK OF DEEP-VEIN THROMBOSIS ASSOCIATED WITH ORAL-CONTRACEPTIVES CONTAINING 3RD-GENERATION PROGESTAGEN [J].

BLOEMENKAMP, KWM ;

ROSENDAAL, FR ;

HELMERHORST, FM ;

BULLER, HR ;

VANDENBROUCKE, JP .

LANCET, 1995, 346 (8990) :1593-1596

[9] Hormone therapy and venous thromboembolism among postmenopausal women -: Impact of the route of estrogen administration and progestogens:: The ESTHER study [J].

Canonico, Marianne ;

Oger, Emmanuel ;

Plu-Bureau, Genevieve ;

Conard, Jacqueline ;

Meyer, Guy ;

Levesque, Herve ;

Trillot, Nathalie ;

Barrellier, Marie-Therese ;

Wahl, Denis ;

Emmerich, Joseph ;

Scarabin, Pierre-Yves .

CIRCULATION, 2007, 115 (07) :840-845

[10] Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users [J].

Cole, J. Alexander ;

Norman, Heather ;

Doherty, Michael ;

Walker, Alexander M. .

OBSTETRICS AND GYNECOLOGY, 2007, 109 (02) :339-346

← 1 2 3 4 5 6 7 →